Abstract Background Baseline comorbidities including renal dysfunction are frequently found in patients treated with transcatheter aortic valve replacement (TAVR) and may increase the risks of acute kidney injury (AKI), although…
Abstract Trans-ulnar access is a viable alternative approach by experienced operators when the radial and femoral arteries cannot be accessed or used to preserve the contralateral radial artery as possible…
Abstract Objectives This study analyzed the outcomes of patients who presented with non-ST-elevation myocardial infarction (NSTEMI) and subsequently underwent orbital atherectomy for severe coronary artery calcification (CAC). Background Patients who…
Abstract Backgrounds Few reports have primarily focused on long-term clinical outcomes in three-vessel disease when patients were treated with either first- or new-generation drug-eluting stents (DES). The purpose of this…
Abstract Background and purposes Drug-coated balloons (DCB) currently represent an alternative to drug-eluting stents (DES) for the treatment of in-stent restenosis and they are also variably used for small coronary…
Abstract Objectives The aim of this study is to evaluate the role of drug-coated balloons (DCB) for the management of bioresorbable vascular scaffold (BVS) restenosis. Methods and results In a…
Abstract Background BioFreedom is a polymer- and carrier-free drug-coated stent that delivers Biolimus A9 to the vessel wall. Our purpose was to evaluate the efficacy and safety of this DCS…
Until a few years ago, the world of percutaneous coronary intervention (PCI) was clear and simple: coronary arteries require metallic stent implantation with controlled release of rapamycin analogues. Stents were…
The use of polymers to modulate the drug release from drug-eluting stents (DES) has undergone several major changes over time. Thirteen years ago, the ELUTES trial first suggested that paclitaxel-coated…
